HK1039337B - 作為抗病毒劑的(1r，順式)-4-(6-氨基-9h-嘌呤-9-基)-2-環戊烯-1-甲醇的氨基磷酸酯及一、二和三磷酸酯 - Google Patents

作為抗病毒劑的(1r，順式)-4-(6-氨基-9h-嘌呤-9-基)-2-環戊烯-1-甲醇的氨基磷酸酯及一、二和三磷酸酯

Info

Publication number
HK1039337B
HK1039337B HK02100897.2A HK02100897A HK1039337B HK 1039337 B HK1039337 B HK 1039337B HK 02100897 A HK02100897 A HK 02100897A HK 1039337 B HK1039337 B HK 1039337B
Authority
HK
Hong Kong
Prior art keywords
purin
phosphoramidate
cyclopentene
cis
tri
Prior art date
Application number
HK02100897.2A
Other languages
English (en)
Other versions
HK1039337A1 (en
Inventor
Mary Daluge Susan
Mcguigan Christopher
Original Assignee
Glaxo Group Ltd
Univ College Cardiff Consultants Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9903090.0A external-priority patent/GB9903090D0/en
Application filed by Glaxo Group Ltd, Univ College Cardiff Consultants Ltd filed Critical Glaxo Group Ltd
Publication of HK1039337A1 publication Critical patent/HK1039337A1/xx
Publication of HK1039337B publication Critical patent/HK1039337B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
HK02100897.2A 1999-02-12 2002-02-05 作為抗病毒劑的(1r，順式)-4-(6-氨基-9h-嘌呤-9-基)-2-環戊烯-1-甲醇的氨基磷酸酯及一、二和三磷酸酯 HK1039337B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9903090.0A GB9903090D0 (en) 1999-02-12 1999-02-12 Therapeutic compounds
US17020599P 1999-12-10 1999-12-10
PCT/EP2000/001045 WO2000047591A1 (en) 1999-02-12 2000-02-10 Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1r, cis)-4-(6-amino-9h-purin-9-yl)-2-cyclopentene-1-methanol as antiviral agents

Publications (2)

Publication Number Publication Date
HK1039337A1 HK1039337A1 (en) 2002-04-19
HK1039337B true HK1039337B (zh) 2003-11-21

Family

ID=26315118

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02100897.2A HK1039337B (zh) 1999-02-12 2002-02-05 作為抗病毒劑的(1r，順式)-4-(6-氨基-9h-嘌呤-9-基)-2-環戊烯-1-甲醇的氨基磷酸酯及一、二和三磷酸酯

Country Status (24)

Country Link
US (1) US7115590B1 (zh)
EP (1) EP1150988B1 (zh)
JP (1) JP2002536452A (zh)
KR (1) KR20010102082A (zh)
CN (1) CN1346360A (zh)
AR (1) AR031975A1 (zh)
AT (1) ATE241633T1 (zh)
AU (1) AU772478B2 (zh)
BR (1) BR0008135A (zh)
CA (1) CA2362662A1 (zh)
CZ (1) CZ20012908A3 (zh)
DE (1) DE60002986T2 (zh)
DK (1) DK1150988T3 (zh)
DZ (1) DZ3007A1 (zh)
ES (1) ES2200820T3 (zh)
HK (1) HK1039337B (zh)
HU (1) HUP0105476A3 (zh)
IL (1) IL144647A0 (zh)
NO (1) NO20013910L (zh)
NZ (1) NZ513450A (zh)
PL (1) PL204458B1 (zh)
PT (1) PT1150988E (zh)
TR (1) TR200102313T2 (zh)
WO (1) WO2000047591A1 (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042255A1 (en) * 1999-12-10 2001-06-14 Glaxo Group Limited (1R,CIS)-4-(4-AMINO-7H-PYRROLO'2,3-I(D) ! PYRIMIDINE-7-YL)-2-CYCLOPENTENE-1-METHANOL DERIVATIVES AS ANTIVIRAL
PE20010915A1 (es) * 1999-12-10 2001-09-29 Glaxo Group Ltd Analogos de (1s, cis)-4-(2-amino-9h-purin-9-il)-2-ciclopenten-1-metanol para uso en el tratamiento de infecciones virales
EA200601591A1 (ru) 2000-05-26 2007-02-27 Айденикс (Кайман) Лимитед Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций
HRP20160074B1 (hr) † 2000-07-21 2021-09-03 Gilead Sciences, Inc. Prolijekovi koji su fosfonatni analozi nukleotida i metode njihovog odabira te njihova priprava
GB0129945D0 (en) * 2001-12-13 2002-02-06 Mrc Technology Ltd Chemical compounds
GB0401088D0 (en) 2004-01-19 2004-02-18 Univ Cardiff Phosphoramidate derivatives
EP2691409B1 (en) 2011-03-31 2018-02-21 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
EP2755983B1 (en) 2011-09-12 2017-03-15 Idenix Pharmaceuticals LLC. Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
AU2013266393B2 (en) 2012-05-22 2017-09-28 Idenix Pharmaceuticals Llc D-amino acid compounds for liver disease
EP2852604B1 (en) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
EA027929B1 (ru) 2012-05-25 2017-09-29 Янссен Сайенсиз Айрлэнд Юси Нуклеозиды на основе урацила и спирооксетана
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
ES2674980T3 (es) 2012-10-08 2018-07-05 Idenix Pharmaceuticals Llc Análogos de 2'-cloro nucleósidos para infección por VHC
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
EP2970357A1 (en) 2013-03-13 2016-01-20 IDENIX Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
WO2014165542A1 (en) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
EP3027636B1 (en) 2013-08-01 2022-01-05 Idenix Pharmaceuticals LLC D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
EP3865136A1 (en) 2016-09-07 2021-08-18 ATEA Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for corona virus treatment
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244896A (en) * 1990-09-14 1993-09-14 Marion Merrell Dow Inc. Carbocyclic adenosine analogs useful as immunosuppressants
GB9505025D0 (en) * 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
US6887707B2 (en) * 1996-10-28 2005-05-03 University Of Washington Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
GB9821058D0 (en) * 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
WO2001042255A1 (en) * 1999-12-10 2001-06-14 Glaxo Group Limited (1R,CIS)-4-(4-AMINO-7H-PYRROLO'2,3-I(D) ! PYRIMIDINE-7-YL)-2-CYCLOPENTENE-1-METHANOL DERIVATIVES AS ANTIVIRAL
US20030096833A1 (en) * 2001-08-31 2003-05-22 Jagtap Prakash G. Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof

Also Published As

Publication number Publication date
US7115590B1 (en) 2006-10-03
AR031975A1 (es) 2003-10-22
ES2200820T3 (es) 2004-03-16
WO2000047591A1 (en) 2000-08-17
EP1150988B1 (en) 2003-05-28
DZ3007A1 (fr) 2003-03-27
NO20013910L (no) 2001-10-10
PL204458B1 (pl) 2010-01-29
IL144647A0 (en) 2002-05-23
KR20010102082A (ko) 2001-11-15
HK1039337A1 (en) 2002-04-19
HUP0105476A2 (en) 2002-06-29
NZ513450A (en) 2004-03-26
DK1150988T3 (da) 2003-09-29
ATE241633T1 (de) 2003-06-15
AU2671300A (en) 2000-08-29
PL350023A1 (en) 2002-10-21
NO20013910D0 (no) 2001-08-10
TR200102313T2 (tr) 2002-03-21
CA2362662A1 (en) 2000-08-17
DE60002986D1 (en) 2003-07-03
CZ20012908A3 (cs) 2002-10-16
BR0008135A (pt) 2002-02-19
AU772478B2 (en) 2004-04-29
DE60002986T2 (de) 2004-05-19
CN1346360A (zh) 2002-04-24
HUP0105476A3 (en) 2002-08-28
JP2002536452A (ja) 2002-10-29
EP1150988A1 (en) 2001-11-07
PT1150988E (pt) 2003-10-31

Similar Documents

Publication Publication Date Title
PL350023A1 (en) Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1r, cis)-4-(6-amino-9h-purin-9-yl)-2-cyclopentene-1-methanol as antiviral agents
AU2002225512A1 (en) Immune system stimulation
IL144171A0 (en) Quinolinecarboxamides as antiviral agents
AU7035501A (en) Improvements relating to medical injector systems
GB0022370D0 (en) Improvements to televisionn system
GB0108235D0 (en) Connector holding structure
GB0114939D0 (en) Luer connector portion
HUP0400732A3 (en) Pharmaceutically active uridine esters
TW467419U (en) Connector holding structure
GB2364833B (en) Connector with retainer
SI1150988T1 (en) Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1r, cis)-4-(6-amino-9h-purin-9-yl)-2-cyclopentene-1-methanol as antiviral agents
ZA200106551B (en) Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1R, cis)-4-(6-amino-9H-purin-9-yl)-2-cyclopentene-1-methanol as antiviral agents.
AU2001284902A1 (en) Human adenosine deaminase
HK1058930A1 (en) Coupled porduction of two esters.
GB9923724D0 (en) Improvements relating to shelving structures
AU1878901A (en) Polysaccharide compound having immune stimulating activity
GB2371925B (en) Connector holding structure
TW454851U (en) Decorating connector structure
GB0012497D0 (en) Antiviral therapy
GB9927686D0 (en) Improvements relating to shelving systems
PL362255A1 (en) Polysaccharide compound having immune stimulating activity
GB2367242B (en) Antiviral treatment
GB9912943D0 (en) Military designs
GB0031487D0 (en) Shelving system
GB0026300D0 (en) Shelving system

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20070210